GHRL and acute respiratory distress syndrome: Although there is an absence of obvious clinical evidence on the therapeutic effects of ghrelin on COVID-19 and the associated complications, preclinical studies have demonstrated that ghrelin is able to ameliorate the severity of acute lung injury by reducing lung fluid accumulation, hypoxemia, and cytokine secretion, all of which also occur in COVID-19-associated acute respiratory distress syndrome [50,51].